Zinc-Alpha 2-Glycoprotein Gene Expression in Adipose Tissue Is Related with Insulin Resistance and Lipolytic Genes in Morbidly Obese Patients by Garrido-Sánchez, Lourdes et al.
Zinc-Alpha 2-Glycoprotein Gene Expression in Adipose
Tissue Is Related with Insulin Resistance and Lipolytic
Genes in Morbidly Obese Patients
Lourdes Garrido-Sa ´nchez
1*
., Eduardo Garcı ´a-Fuentes
2,3*
., Diego Ferna ´ndez-Garcı ´a
3,4, Xavier Escote ´
1,
Juan Alcaide
2,4, Pablo Perez-Martinez
3,5, Joan Vendrell
1, Francisco J. Tinahones
3,4
1CIBERDEM, Hospital Universitari Joan XXIII, Pere Virgili Institute, Tarragona, Spain, 2Fundacio ´n IMABIS, Malaga, Spain, 3Ciber Fisiopatologı ´a Obesidad y Nutricio ´n
(CIBEROBN), Malaga, Spain, 4Servicio de Endocrinologı ´a y Nutricio ´n, Hospital Clı ´nico Virgen de la Victoria, Malaga, Spain, 5Servicio de Medicina Interna, Hospital
Universitario Reina Sofia, Co ´rdoba, Spain
Abstract
Objective: Zinc-a2 glycoprotein (ZAG) stimulates lipid loss by adipocytes and may be involved in the regulation of adipose
tissue metabolism. However, to date no studies have been made in the most extreme of obesity. The aims of this study are
to analyze ZAG expression levels in adipose tissue from morbidly obese patients, and their relationship with lipogenic and
lipolytic genes and with insulin resistance (IR).
Methods: mRNA expression levels of PPARc, IRS-1, IRS-2, lipogenic and lipolytic genes and ZAG were quantified in visceral
(VAT) and subcutaneous adipose tissue (SAT) of 25 nondiabetic morbidly obese patients, 11 with low IR and 14 with high IR.
Plasma ZAG was also analyzed.
Results: The morbidly obese patients with low IR had a higher VAT ZAG expression as compared with the patients with high
IR (p=0.023). In the patients with low IR, the VAT ZAG expression was greater than that in SAT (p=0.009). ZAG expression
correlated between SAT and VAT (r=0.709, p,0.001). VAT ZAG expression was mainly predicted by insulin, HOMA-IR,
plasma adiponectin and expression of adiponectin and ACSS2. SAT ZAG expression was only predicted by expression of
ATGL.
Conclusions: ZAG could be involved in modulating lipid metabolism in adipose tissue and is associated with insulin
resistance. These findings suggest that ZAG may be a useful target in obesity and related disorders, such as diabetes.
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Introduction
Classically, obesity has been considered to be associated with a
proinflammatory state, generating an increased incidence of
dyslipidemia and insulin resistance (IR) [1]. This association
seems to be mediated by the release of various proinflammatory
adipokines and cytokines (e.g., leptin, adiponectin, TNF alpha, IL-
6) by adipose tissue [2–4]. These proteins act either in an
autocrine/paracrine/endocrine manner to locally regulate the
adipocyte metabolism or as endocrine signals.
Zinc-a2 glycoprotein (ZAG), a protein secreted by different
organs, such as liver, breast, lung and prostate [5], has recently
been found to be expressed in both mature adipocytes [6,7] and in
visceral and subcutaneous adipose tissue in animal models (i.e.,
mice, rats) and humans [8,9]. ZAG was initially identified as the
lipid mobilizing factor associated with loss of adipose tissue in
patients with cancer cachexia [10,11]. Various studies have shown
that ZAG gene expression is reduced in subcutaneous adipose
tissue from obese persons [7,12]. Moreover, studies in ZAG-
deficient mice show that the intake of a standard or a high-fat diet
(HFD) increases the body weight in comparison to identically
treated wild-type mice [13]. Likewise, ZAG overexpression in
HFD-fed obese mice results in a reduction of body weight,
epididymal fat mass and percentage of epididymal fat [14].
Both in vivo and in vitro studies have shown that ZAG stimulates
lipid loss by adipocytes [15,16]. In addition, ZAG may also
stimulate lipolysis through interaction with b3-adrenoreceptors,
suggesting a role in lipid catabolism [10,17]. The incubation of
ZAG with adipocytes isolated from murine adipose tissue greatly
stimulates glycerol release in a dose-dependent manner [10]. The
lipolytic effect of ZAG on adipocytes [15], together with a high
expression in adipose tissue during fat loss in patients with cancer
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regulation of adipose tissue metabolism.
Lipolysis in healthy subjects is extremely sensitive to the action
of insulin. Recently, we have shown that the expression of
lipogenic and lipolytic genes was altered in morbidly obese patients
and was influenced by the adipose tissue location and clinical
phenotype, such as IR [18]. Several studies have shown that ZAG
gene expression is associated negatively with plasma insulin levels
[7,14,19]. Mracek et al. [7] suggested that ZAG, as a major
adipokine, may have a protective role in the susceptibility to
obesity and its related IR. Furthermore, the overexpression of
ZAG in 3T3-L1 adipocytes provokes an increased expression of
adiponectin, which is highly involved in the control of IR [20].
This all suggests that ZAG may be a gene involved in the
regulation of body weight and insulin sensitivity [15,21].
Despite evidence from animal and human in vivo studies, few
data exist about ZAG levels in the most extreme form of obesity.
All the above evidence led us to hypothesize that ZAG gene
expression in adipose tissue from morbidly obese patients may
have a relationship with the expression of these lipogenic and
lipolytic genes. To test this hypothesis, we analyzed ZAG gene
expression levels in visceral and subcutaneous adipose tissue from
a group of morbidly obese patients, and their relationship with
lipogenic and lipolytic genes and with IR.
Results
Anthropometric and biochemical characteristics
Table 1 summarizes the characteristics of the morbidly obese
patients according to whether they had low IR or high IR.
Morbidly obese patients with high IR had a larger waist and
higher serum levels of glucose, triglycerides, insulin, CRP and
HOMA-IR (Table 1). Plasma adiponectin levels were significantly
lower in the morbidly obese patients with high IR. Serum ZAG
was similar between the two groups of morbidly obese patients.
ZAG gene expression according to insulin resistance
The morbidly obese patients with low IR had a significantly
higher ZAG gene expression in VAT as compared with the patients
with high IR (p=0.023) (Figure 1). In SAT, patients with low IR
had higher ZAG gene expression though the difference was not
significant (p=0.232). No gender dimorphism was detected for
ZAG gene expression.
In the morbidly obese patients with low IR, the ZAG gene
expression in VAT was significantly greater than that in SAT
(p=0.009) (Figure 1). No significant differences were detected
between VAT and SAT in the morbidly obese patients with high
IR (p=0.534) (Figure 1).
Relation between ZAG gene expression and
anthropometric and biochemical characteristics
The serum ZAG levels did not correlate significantly with any of
the anthropometric or biochemical variables studied (data not
shown). ZAG gene expression levels in VAT and SAT correlated
positively with age (r=0.638, p=0.001; and r=0.580, p=0.004,
respectively). However, ZAG gene expression in VAT and SAT
correlated negatively with weight (r=20.585, p=0.002; and
r=20.610, p=0.002, respectively), BMI (r=20.442, p=0.036;
and r=20.524, p=0.010 respectively) (Figure 2a, figure 2b) and
waist circumference (r=20.773, p,0.001; and r=20.636,
p=0.001, respectively). ZAG gene expression in VAT correlated
negatively with insulin (r=20.565, p=0.005) and HOMA-IR
(r=20.457, p=0.029) (Figure 2c), and positively with the
circulating adiponectin levels (r=0.509, p=0.013) (Figure 2e).
The ZAG gene expression in VAT and SAT did not correlate
significantly with any of the other anthropometric and biochemical
variables studied (data not shown).
Relationship between ZAG gene expression and lipid
metabolism
The serum ZAG levels did not correlate significantly with the
expression of any of the genes studied or the expression of ZAG in
VAT and SAT (data not shown).
Associations between ZAG gene expression with other genes in
VAT and SAT were explored. ZAG gene expression in VAT
correlated strongly with ZAG gene expression in SAT (r=0.709,
p,0.001). In VAT, ZAG gene expression correlated significantly
and positively with the expression of PPARc, ACSS2, DGAT1,
ATGL, IRS-1, IRS-2 and adiponectin (Table 2). In SAT, ZAG gene
expression correlated significantly and positively with PPARc,
ACC1, DGAT1, ATGL, HSL and adiponectin (Table 3).
In order to strengthen the independence of these associations as
predictors of ZAG gene expression, a multiple regression analysis
model was constructed for each depot. In the VAT depot model,
age, BMI, waist circumference, insulin, circulating adiponectin
levels, HOMA-IR and mRNA expression of genes for adiponectin,
ACSS2, DGAT1 and ATGL were selected as independent variables.
VAT ZAG gene expression was mainly predicted (R
2=0.959) by
insulin (B=20.088, p=0.030), HOMA-IR (B=0.320, p=0.025),
circulating adiponectin levels (B=0.146, p=0.045) and expression
of adiponectin (B=0.515, p=0.039) and ACSS2 (B=21.346,
p=0.014). In the SAT model, age, BMI, waist circumference,
HOMA-IR and mRNA expression of adiponectin, ACC1, DGAT1,
ATGL and HSL were included as independent variables. SAT ZAG
gene expression (R
2=0.980) was only predicted by ATGL gene
expression (B=0.272, p=0.021).
Table 1. Anthropometric and biochemical variables in the
morbidly obese patients classified according to their insulin
resistance (IR).
Low IR High IR P
N (men/women) 11 (5/6) 14 (7/7) Ns
Age (years) 40.9610.6 38.367.9 Ns
Weight (kg) 134.55624.15 159.37630.39 0.051
BMI (Kg/m
2) 50.668.09 57.3265.95 Ns
Waist (cm) 131.1613.68 148.5616.80 0.008
Hip (cm) 149.5613.41 159.1616.97 Ns
Glucose (mmol/L) 4.960.372 5.7360.970 0.001
Cholesterol (mmol/L) 4.8660.963 4.8260.933 Ns
Triglycerides (mmol/L) 1.1260.684 1.7860.646 0.003
FFA (mmol/L) 0.43760.147 0.54060.180 Ns
Insulin (pmol/L) 91.04624.93 293.14695.35 ,0.001
HOMA-IR 2.8560.734 11.4664.73 ,0.001
Leptin (ng/mL) 61.82631.89 64.82625.34 Ns
Adiponectin (ng/mL) 10.2162.95 7.0364.40 0.025
CRP (mg/L) 3.8863.25 10.1569.14 0.042
Serum ZAG (mg/L) 36.21610.33 37.6269.64 Ns
The results are given as the mean 6 SD. BMI: body mass index; FFA: Free fatty
acids; HOMA-IR: homeostasis model assessment of insulin resistance index, CRP:
C-reactive protein; ZAG: zinc alpha-2 glycoprotein. Ns: Not significant.
doi:10.1371/journal.pone.0033264.t001
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This study is the first to analyze the ZAG expression in the most
extreme form of obesity. We show that VAT and SAT ZAG
expression and its relation with the insulin resistance is different.
We found a inverse relation between the degree of IR and the
ZAG gene expression in VAT. Furthermore, the ZAG gene
expression showed a direct relation with the genetic expression of
lipolytic enzymes in both VAT and SAT.
No significant differences were found between morbidly obese
patients with low IR and those with high IR in the circulating
serum ZAG levels. These findings corroborate those of Stejskal et
al. [22], who found no differences in serum ZAG concentrations
between obese patients with the metabolic syndrome and
otherwise healthy controls. Another study also failed to find
significant differences in serum ZAG concentrations between
overweight patients and obese patients, nor between patients with
and without the metabolic syndrome [23]. However, recent studies
in humans have reported reductions in serum ZAG levels in obese
patients [14,19]. Given that ZAG is produced by several different
tissues [8], serum levels may be influenced by the secretion of each
particular tissue. In addition, the clearance of ZAG in the
circulation might be altered in obesity.
In our study ZAG gene expression in VAT and SAT was
inversely associated with different anthropometric variables, such
as weight, BMI and waist circumference. Previous studies have
shown a down-regulation of the expression of this adipokine in
obese patients [12,24]. We show that even in the morbidly obese
patients, the inverse relationship between BMI and ZAG gene
expression is maintained. Studies in mice show that the
overexpression of ZAG is associated with a reduced body weight
and percentage of epididymal fat [14]. Animal studies have
demonstrated a beneficial effect of ZAG protein administration on
reducing body weight by decreasing fat content in mice, even
though they maintained normal eating habits [10]. Although ZAG
gene expression has been shown to be inversely related to
adiposity, its regulation in obesity remains to be established.
In this study we noted a reduction in ZAG gene expression in
the morbidly obese patients with high IR, though the difference
was not significant in VAT. The negative association found
between IR and ZAG gene expression in VAT is in agreement
with other studies [7,14,23]. Mracek et al. [7] suggested that ZAG
may have a protective role in the susceptibility to obesity and its
related IR. Others have demonstrated that treatment with ZAG
stimulates the use of glucose and increases lipid oxidation in
different murine tissues [17]. The positive association found
between the expression of ZAG gene and IRS-1 and IRS-2
strengthens the case for the implication of ZAG in mechanisms
regulating IR. It is well accepted that IRS-1 is a main component
in the activation of insulin signalling in adipose tissue [25].
Different studies have shown a lower amount of IRS-1 in 30% of
subjects at high risk for type 2 diabetes, such as first-degree
relatives of type 2 diabetic and obese subjects [26,27]. In earlier
studies we found elevated levels of IRS-1 gene expression in
morbidly obese patients with low IR compared with those with
high IR [28].
In this context, our results show that IR and plasma adiponectin
circulating levels and expression are the main variables signifi-
cantly associated with the ZAG gene expression levels. As in other
studies made in non-morbidly obese patients [7,23], our results
show a positive association between ZAG gene expression, in both
VAT and SAT, and the adiponectin gene expression levels in
morbidly obese patients. In animal models of type 2 diabetes a role
for ZAG as a modulator of adipocyte endocrine signalling at a
local site has been proposed. In 3T3-L1, the overexpression of
ZAG leads to an increased expression of adiponectin [21]. In
addition, a positive association has also been found between ZAG
and PPARc gene expression. This nuclear receptor is involved in
the regulation of ZAG synthesis [6]. It has previously been shown
that treatment with rosiglitazone, a selective PPARc agonist,
Figure 1. ZAG gene expression levels in visceral (VAT) (&) and subcutaneous (SAT) (%) adipose tissue. MO low IR: morbidly obese
persons with low insulin resistance. MO high IR: morbidly obese persons with high insulin resistance. Adipose tissue expression levels for each gene
were normalized using cyclophilin A. The results are given as the mean 6 SD.
doi:10.1371/journal.pone.0033264.g001
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levels in human adipocytes [6]. These findings all suggest the
existence of a regulatory mechanism between both adipokines
acting in a coordinated manner, with potential implications in
obesity and type 2 diabetes mellitus [29].
The underlying mechanisms for the different findings in VAT
compared to SAT are unknown. ZAG gene expression was greater
in VAT than in SAT, but only in morbidly obese patients with a
low IR. The endocrine function, and response to insulin and other
hormones differ between SAT and VAT. These actions are also
markedly altered in the adipose tissue of obese persons [30]. This
might explain the tissue-specific expression of ZAG gene. This
different expression may also be related with the concept that
VAT contributes to the morbidity associated with the metabolic
syndrome features.
SeveralkeyenzymesinlipidmetabolismweredeterminedinVAT
and SAT of morbidly obese patients. Our results also suggest that
ZAG may be involved in the regulation of lipid metabolism. ZAG
gene expression in morbidly obese patients is positively associated
with the expression of lipogenic (ACC1, ACSS2 and DGAT1) and
lipolytic (ATGL and HSL) genes in VAT and SAT. We have
previously shown in slim and overweight persons an association of
ZAG gene expression with the expression of lipolytic genes [23].
Studies inZAG overexpression miceshow a decrease in FAS, ACC1
and DGAT mRNA and a increase in HSL mRNA in epididymal
adipose tissue [14]. The discrepancy found in the relation between
ZAG gene expression and the lipogenic enzymes may be due to the
type of sample studied. Our study was undertaken in persons with
extreme obesity, in which we had earlier shown that the expression
of both lipogenic and lipolytic genes was significantly raised [18].
Figure 2. Correlations between ZAG gene expression levels in adipose tissue and anthropometric and biochemical variables. (A)
Comparison of ZAG gene expression levels in visceral adipose tissue (VAT) and BMI. (B) Comparison of ZAG gene expression levels in subcutaneous
adipose tissue (SAT) and BMI. (C) Comparison of ZAG gene expression levels in VAT and HOMA-IR. (D) Comparison of ZAG gene expression levels in
VAT and adiponectin circulating levels. (&) Morbidly obese persons with low insulin resistance. (%) Morbidly obese persons with high insulin
resistance.
doi:10.1371/journal.pone.0033264.g002
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stimulates lipolysis in vitro in a dose-dependent manner [10,31].
The mobilization of stored triglycerides from adipose tissue is
mediated mainly by the activation of two genes: HSL and ATGL
[30]. HSL was elevated in adipose tissue from ZAG-overexpress-
ing transgenic mice which exhibit decreased body weight and
epididymal fat [14]. In vivo, the administration of ZAG to mice
induces a reduction in body fat and an increase in serum FFA by
HSL activation [15,16]. Although HSL was initially considered to
be the rate-limiting enzyme for lipolysis, recent data suggest that
ATGL may also be rate limiting [32]. In this context, SAT from
morbidly obese patients showed that, although ZAG and HSL
gene expression are positively correlated, ATGL gene expression is
the most important determinant of ZAG gene expression in these
patients. Our results suggest that ZAG gene expression might be
related to its function in modulating lipid metabolism [33].
In conclusion, this study adds to previous results obtained in
non-morbidly obese patients. ZAG is closely linked to obesity. The
ZAG gene expression may be involved in the regulation of lipid
metabolism in morbidly obese patients, but all of them
(ZAG+lipogenic and lipolytic genes) also could be regulated
through the same signalling pathway, meaning that ZAG does not
regulates these genes. The relationship between ZAG gene
expression and IR and adiponectin in human adipose tissue
reinforces previous experimental data and warrants further
mechanistic studies as a useful target in obesity and related
disorders, such as diabetes.
Materials and Methods
Subjects
The study included 25 nondiabetic morbidly obese patients
(body mass index (BMI) 57.465.2 Kg/m
2), 11 with low IR
(homeostasis model assessment of insulin resistance index
(HOMA-IR),4.7) and 14 with high IR (HOMA-IR.8) [18,29].
The cut-off points for the HOMA-IR were taken from previous
studies carried out in a healthy population with no carbohydrate
metabolism disorders [18,29]. All the patients underwent bilio-
pancreatic diversion of Scopinaro. Patients were excluded if they
had type 2 diabetes mellitus, cardiovascular disease, arthritis, acute
inflammatory disease, infectious disease, or were receiving drugs
that could alter the lipid profile or the metabolic parameters at the
time of inclusion in the study. The weight of all the persons had
been stable for at least one month and none had renal
involvement. All participants gave their informed consent and
the study was reviewed and approved by the Ethics and Research
Committee of Virgen de la Victoria Clinical University Hospital,
Malaga, Spain.
Laboratory measurements
Blood samples were collected after a 12-hour fast. The serum
was separated and immediately frozen at 280uC. Serum
biochemical parameters were measured in duplicate. Serum
glucose, cholesterol, HDL cholesterol, triglycerides (Randox
Laboratories Ltd., Antrium, UK) and free fatty acids (FFA)
(WAKO Chemicals, Richmond, VA) were measured by standard
enzymatic methods. Adiponectin levels were measured by enzyme
immunoassay (ELISA) kits (DRG Diagnostics, Marburg, Ger-
many). High-sensitivity C-reactive protein (CRP) levels were
measured by ELISA kit from BLK Diagnostics (Badalona, Spain).
Leptin levels were measured by ELISA kit from Mediagnost
(Reutlingen, Germany). The insulin was analyzed by an
immunoradiometric assay (IRMA) (BioSource International,
Camarillo, CA), showing a 0.3% cross-reaction with proinsulin.
Plasma ZAG levels were measured by sandwich ELISA (Bio-
Vendor Laboratory Medicine, Inc., Palackeho, Czech Republic).
The HOMA-IR was calculated from fasting insulin and glucose
with the following equation: HOMA-IR=fasting insulin (mIU/
mL)6fasting glucose (mol/L)/22.5.
Visceral and subcutaneous adipose tissue mRNA
We analyzed the relative basal mRNA expression levels of ZAG
and lipogenic and lipolytic genes in epiploic visceral adipose tissue
(VAT) and abdominal subcutaneous adipose tissue (SAT). VAT
and SAT were obtained during bariatric surgery in the morbidly
obese patients [18,34]. The biopsy samples were washed in
physiological saline and immediately frozen in liquid nitrogen.
Biopsy samples were maintained at 280uC until analysis. Frozen
Table 2. Bivariate correlations (p) between ZAG gene
expression and other genes expression in visceral adipose
tissue.
ZAG
PPARc 0.718 (0.001)
ACC1 Ns
ACSS2 0.689 (0.002)
DGAT1 0.689 (0.002)
ATGL 0.645 (0.005)
HSL Ns
Adiponectin 0.684 (0.002)
IRS-1 0.616 (0.048)
IRS-2 0.886 (0.003)
R: Spearman’s Rho; ACC1: acetyl-coenzime carboxilase 1; ACSS2: acyl-CoA
synthetase short-chain family member 2; DGAT1: acyl Coenzyme A:cholesterol
acyltransferase; ATGL: adipose triglyceride lipase; HSL: Hormose-sensitive lipase;
IRS_1: insulin receptor substrate 1 IRS_2: insulin receptor substrate 2; PPARc:
peroxisome proliferator-activated receptor-c, VAT: visceral adipose tissue; Ns:
not significant.
doi:10.1371/journal.pone.0033264.t002
Table 3. Bivariate correlations (p) between ZAG gene
expression and other genes expression in subcutaneous
adipose tissue.
ZAG
PPARc 0.541 (0.030)
ACC1 0.721 (0.002)
ACSS2 Ns
DGAT1 0.474 (0.048)
ATGL 0.638 (0.008)
HSL 0.568 (0.022)
Adiponectin 0.750 (0.001)
IRS-1 Ns
IRS-2 Ns
R: Spearman’s Rho; PPARc: peroxisome proliferator-activated receptor-c, ACC1:
acetyl-coenzime carboxilase 1; ACSS2: acyl-CoA synthetase short-chain family
member 2; DGAT1: acyl Coenzyme A:cholesterol acyltransferase; ATGL: adipose
triglyceride lipase; HSL: Hormose-sensitive lipase; IRS_1: insulin receptor
substrate 1 IRS_2: insulin receptor substrate 2; SAT: subcutaneous adipose
tissue; Ns: not significant.
doi:10.1371/journal.pone.0033264.t003
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Staufen, Germany). Total RNA was extracted by RNeasy lipid
tissue midi kit (QIAGEN Science, Hilden, Germany), and total
RNA was treated with 55 U RNase-free deoxyribonuclease
(QIAGEN Science, Hilden, Germany) following the manufactur-
er’s instructions. The purity of the RNA was determined by the
absorbance260/absorbance280 ratio on the Nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientific Inc. Waltham, MA).
The integrity of total purified RNA was checked by denaturing
agarose gel electrophoresis and ethidium bromide staining. Total
RNA was reverse transcribed to cDNA by using a high-capacity
cDNA reverse transcription kit with RNase inhibitor (Applied
Biosystems, Foster City, CA). The cDNA was used for quantitative
real-time PCR with duplicates. The amplifications were performed
using a MicroAmpH Optical 96-well reaction plate (Applied
Biosystems, Foster City, CA) on an ABI 7500 Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA). RT-qPCR
reactions were carried out for all genes using specific TaqManH Gene
ExpressionAssays(Applied Biosystems,FosterCity,CA).We analyzed
the relative basal mRNA expression levels of ZAG (Hs00426651_m1,
RefSeq. NM_00185.3), adiponectin (Hs00605917_m1, RefSeq.
NM_001177800.1 and NM_004797.3), insulin receptor substrate 1
(IRS-1) (Hs00178563_m1, RefSeq. NM_005544.2), insulin receptor
substrate 2 (IRS-2) (Hs00275843_s1, RefSeq. NM_003749.2), perox-
isome proliferator-activated receptor-c (PPARc) (Hs00234592_m1,
RefSeq. NM_005037.5, NM_015869.4, NM_138711.3 and NM_
138712.3) and genes involved in lipogenesis or lipolysis: acyl-
CoA:cholesterol acyltransferase (DGAT1) (Hs00201385_m1, refSeq.
NM_012079.4), acetyl-CoA carboxilase 1 (ACC1) (Hs00167385_m1,
RefSeq. NM_ 198834.1, NM_198836.1, NM_198837.1, NM_
198838.1 and NM_198839.1),acyl-CoA synthetaseshort-chainfamily
member 2 (ACSS2) (Hs00218766_m1, RefSeq. NM_001076552.2,
NM_018677.3 and NR_028046.1), adipose triglyceride lipase (ATGL)
(Hs00386101_m1, RefSeq. NM_020376.3) and hormone-sensitive
lipase (HSL) (Hs00193510_m1, RefSeq. NM_005357.2). The cycle
threshold (Ct) value for each sample was normalized with the
expression of cyclophilin A (PPIA) (4326316E, RefSeq. NM_
021130.3). During PCR, the Ct values for each amplified product
were determined using a threshold value of 0.1. SDS software 2.3 and
RQ Manager 1.2 (Applied Biosystems, Foster City, CA) were used to
analyze the results with the comparative Ct method (2
2DDCt). All data
were expressed as an n-fold difference relative to the calibrator (a
mixture of the SAT and VAT tissues was used as the calibrator
sample).
Statistical analysis
Based on previous results from our group [18], the study was
designed to make a comparative analysis between the two study
groups, with a standard deviation of the PPARc mRNA
expression of 0.65, a capacity to detect a change in PPARc
mRNA expression of 0.90 and a detection power of 80%. For an
a=0.05, the minimum sample size needed for each group was 10
cases. The statistical analysis was done with SPSS (Version 11.5 for
Windows; SPSS, Chicago, IL). Because most of the parameters
analyzed do not have a normal distribution, we used non-
parametric tests. Comparison between the results of the morbidly
obese patients with low or high IR was made with the Mann-
Whitney test. The Spearman correlation coefficients were
calculated to estimate the correlations between variables. Multiple
linear regressions were used to determine the association between
variables. Values were considered to be statistically significant
when the p#0.05. The results are given as the mean 6 SD.
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